By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Peregrine Pharmaceuticals, Inc. 

14272 Franklin Avenue
Suite 100
Tustin  California  92780  U.S.A.
Phone: 714-508-6000 Fax: 714-838-5817




Company News
Peregrine (PPHM) Presents Preclinical Data Demonstrating PS-Targeting Antibodies Significantly Enhance The Anti-Tumor Activity Of Multiple Checkpoint Targeting Agents In Model Of Triple Negative Breast Cancer (TNBC) 9/27/2016 7:39:24 AM
Peregrine (PPHM) Provides Update On Oral Presentation Of Top-Line Data From Phase III SUNRISE Trial Of Bavituximab At European Society For Medical Oncology (ESMO) 2016 Congress 9/21/2016 10:36:21 AM
Peregrine (PPHM) Reports Financial Results For First Quarter Of Fiscal Year 2017 And Recent Developments 9/9/2016 7:49:21 AM
Peregrine (PPHM) Declares Quarterly Dividend On Its Series E Convertible Preferred Stock 9/7/2016 10:06:42 AM
Peregrine (PPHM) To Report Financial Results For First Quarter Of Fiscal Year 2017 After Market Close On September 8, 2016 9/2/2016 8:18:38 AM
Peregrine (PPHM) Reports Financial Results For Quarter And Fiscal Year Ended April 30, 2016 And Recent Developments 7/15/2016 8:08:43 AM
Peregrine (PPHM) Licenses Novel Exosome-Based Cancer Detection And Monitoring Technology From UT Southwestern Medical Center 7/14/2016 8:08:05 AM
Peregrine (PPHM) Nixes Planned Trials for Bavituximab, But Hints at a Future Trial with AstraZeneca PLC (AZN)’s Durvalumab 6/2/2016 8:09:53 AM
Peregrine (PPHM) Release: Preclinical Data Presented At AACR Annual Meeting Demonstrate Enhanced Therapeutic Benefit Of Combining A Ps-Targeting Antibody With Anti-Pd-1 Therapy In Models Of Triple Negative Breast Cancer (TNBC) 4/20/2016 3:15:37 PM
Peregrine (PPHM) Announces Formal Commissioning Of New, State-Of-The-Art Commercial Manufacturing Facility 3/7/2016 8:27:30 AM